Scribe Therapeutics Inc.
SCTXScribe Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $51.2 million.
After hours trading: 12.00, down 0.58%, last trade Fri 7:39pm Eastern.
Follow SCTX
Alert me
Scribe Therapeutics Inc. (SCTX) Return on invested capital
Return on invested capital, annual
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| QTTB Q32 Bio Inc. compare | 0.00% |
| EIKN Eikon Therapeutics, Inc. compare | 0.00% |
| PRLD Prelude Therapeutics Incorporated compare | 0.00% |
| OCGN Ocugen, Inc. compare | 0.00% |
| CAMP CAMP4 Therapeutics Corporation compare | 0.00% |
| AUTL Autolus Therapeutics PLC Sponsored ADR compare | 0.00% |
| SABS SAB Biotherapeutics, Inc. compare | −48.4% |
| IPSC Century Therapeutics, Inc. compare | −71.5% |
| SCTX Scribe Therapeutics Inc. | — |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.06% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)